Prime Medicine, Inc. (PRME) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 31.69M USD | Liabilities, Current |
| Cash and equivalents | 47.45M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 47.62M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $31.69M | $47.45M | $47.62M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $36.29M | $64.11M | $71.39M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $37.45M | $63.03M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $35.02M | $71.40M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $34.11M | $53.80M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $34.29M | $91.88M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $37.96M | $182.48M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $37.88M | $117.98M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $20.75M | $55.60M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $24.44M | $94.16M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $56.42M | $41.57M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $39.37M | $43.96M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $28.72M | $120.58M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $23.87M | $133.46M | $109.92M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $26.71M | $187.62M | $98.47M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $22.22M | $47.95M | $89.17M | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $92.24M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $164.25M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $57.98M | $185.42M | $68.24M | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $200.66M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $36.98M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |